Cover Image
市場調查報告書

經導管心臟瓣膜:醫療設備的開發平台評估

Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2018

出版商 GlobalData 商品編碼 408772
出版日期 內容資訊 英文 307 Pages
訂單完成後即時交付
價格
Back to Top
經導管心臟瓣膜:醫療設備的開發平台評估 Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2018
出版日期: 2018年06月08日 內容資訊: 英文 307 Pages
簡介

本報告提供全球經導管心臟瓣膜市場上主要的開發中產品 (醫療設備) 及其臨床實驗的進展調查,再彙整產品特性比較分析 (臨床實驗的各進展階段) ,主要企業簡介及代表性產品,近來的市場動靜 (資本交易·產業聯盟等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 經導管心臟瓣膜概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 經導管心臟瓣膜:各企業現在臨床實驗中的開發中產品

  • 經導管心臟瓣膜的企業:各臨床實驗階段的開發中產品
  • 經導管心臟瓣膜:各臨床實驗階段的開發中產品

第5章 經導管心臟瓣膜的企業·產品概要

  • Abbott Vascular Inc.
    • 開發中產品及進行中的臨床實驗概要
  • Admedus Ltd
  • Advanced Bio Prosthetic Surfaces Ltd.
  • Aegis Surgical Limited
  • Annulon
  • AorTech International Plc
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Celyad SA
  • Cephea Valve Technologies, Inc.
  • Children's Hospital Boston
  • Clemson University
  • Colibri Heart Valve, LLC
  • Direct Flow Medical Inc
  • Dura LLC
  • Edwards Lifesciences Corp
  • Emory University
  • Endoluminal Technology Research, LLC
  • Hansen Medical Inc
  • HighLife SAS
  • HLT, Inc.
  • InterVene Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • Mayo Clinic US
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • Micro Interventional Devices, Inc.
  • MicroPort Scientific Corp
  • Mitralix Ltd.
  • MitrAssist Ltd.
  • MValve Technologies Ltd.
  • NaviGate Cardiac Structures, Inc.
  • Neovasc Inc
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • SAS Cormove
  • Sino Medical Sciences Technology Inc.
  • St. Jude Medical Inc
  • Symetis AG
  • Thubrikar Aortic Valve, Inc.
  • Universiteit Utrecht
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Valtech Cardio Ltd
  • Venus MedTech
  • Xeltis AG

第6章 經導管心臟瓣膜市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0599EPD

GlobalData's Medical Devices sector report, "Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2018" provides an overview of Transcatheter Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transcatheter Heart Valves under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Heart Valves and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Heart Valves under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 16

2 Introduction 17

  • 2.1 Transcatheter Heart Valves Overview 17

3 Products under Development 18

  • 3.1 Transcatheter Heart Valves - Pipeline Products by Stage of Development 18
  • 3.2 Transcatheter Heart Valves - Pipeline Products by Segment 19
  • 3.3 Transcatheter Heart Valves - Pipeline Products by Territory 20
  • 3.4 Transcatheter Heart Valves - Pipeline Products by Regulatory Path 22
  • 3.5 Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 23
  • 3.6 Transcatheter Heart Valves - Ongoing Clinical Trials 24

4 Transcatheter Heart Valves - Pipeline Products under Development by Companies 25

  • 4.1 Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development 25
  • 4.2 Transcatheter Heart Valves - Pipeline Products by Stage of Development 28

5 Transcatheter Heart Valves Companies and Product Overview 32

  • 5.1 4C Medical Technologies Inc Company Overview 32
  • 5.2 Admedus Ltd Company Overview 33
  • 5.3 Aegis Surgical Limited Company Overview 34
  • 5.4 Annulon Company Overview 35
  • 5.5 AorTech International Plc Company Overview 36
  • 5.6 AorTx, Inc. Company Overview 37
  • 5.7 Arbor Surgical Technologies, Inc. Company Overview 38
  • 5.8 Boston Children's Hospital Company Overview 39
  • 5.9 Boston Scientific Corp Company Overview 40
  • 5.10 Carena Healthcare Ltd Company Overview 63
  • 5.11 Cephea Valve Technologies, Inc. Company Overview 64
  • 5.12 Children's Hospital Boston Company Overview 65
  • 5.13 Clemson University Company Overview 66
  • 5.14 Colibri Heart Valve, LLC Company Overview 67
  • 5.15 Daidalos Solutions BV Company Overview 74
  • 5.16 Direct Flow Medical Inc (Inactive) Company Overview 76
  • 5.17 DSM Dyneema BV Company Overview 80
  • 5.18 Dura LLC Company Overview 81
  • 5.19 Edwards Lifesciences Corp Company Overview 83
  • 5.20 Emory University Company Overview 102
  • 5.21 Endoluminal Technology Research, LLC Company Overview 103
  • 5.22 Florida International University Company Overview 105
  • 5.23 HighLife SAS Company Overview 106
  • 5.24 HLT, Inc. Company Overview 109
  • 5.25 JC Medical, Inc. Company Overview 112
  • 5.26 JenaValve Technology GmbH Company Overview 117
  • 5.27 LivaNova PLC Company Overview 120
  • 5.28 Mayo Clinic Company Overview 123
  • 5.29 Medtronic plc Company Overview 124
  • 5.30 Meril Life Sciences Pvt Ltd Company Overview 137
  • 5.31 Micro Interventional Devices, Inc. Company Overview 138
  • 5.32 MicroPort Scientific Corp Company Overview 139
  • 5.33 Mitralix Ltd. Company Overview 142
  • 5.34 MitrAssist Ltd. Company Overview 143
  • 5.35 MValve Technologies Ltd. Company Overview 144
  • 5.36 NaviGate Cardiac Structures, Inc. Company Overview 147
  • 5.37 Neovasc Inc Company Overview 151
  • 5.38 PolyNova Cardiovascular LLC (Inactive) Company Overview 154
  • 5.39 Polyvascular Corp Company Overview 155
  • 5.40 RegenaGraft Company Overview 156
  • 5.41 ReValve Med Inc Company Overview 157
  • 5.42 SAS Cormove Company Overview 158
  • 5.43 Sino Medical Sciences Technology Inc Company Overview 159
  • 5.44 St. Jude Medical LLC Company Overview 160
  • 5.45 Symetis SA Company Overview 164
  • 5.46 Thubrikar Aortic Valve, Inc. Company Overview 175
  • 5.47 Trinity College Dublin Company Overview 176
  • 5.48 University College London Company Overview 177
  • 5.49 University of California San Francisco Company Overview 179
  • 5.50 University of Cambridge Company Overview 180
  • 5.51 University of Iowa Company Overview 181
  • 5.52 Valtech Cardio Ltd Company Overview 183
  • 5.53 Vascular Concepts Ltd Company Overview 186
  • 5.54 Venus MedTech Company Overview 187
  • 5.55 Xeltis AG Company Overview 194

6 Transcatheter Heart Valves- Recent Developments 195

  • 6.1 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 195
  • 6.2 May 31, 2018: JC Medical Announces First-in-Human Treatment with the Unique Transfemoral J-Valve TAVI Device for Aortic Regurgitation 195
  • 6.3 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 196
  • 6.4 May 22, 2018: Treatment with Abbott s Portico Transcatheter Aortic Valve Showed Portico is Safe and Reduces Severe Aortic Stenosis at 30 Days in Real-World Setting 198
  • 6.5 May 22, 2018: Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve 200
  • 6.6 May 22, 2018: Admedus: TAVR Progress Continues With Filing of New Provisional Patents 200
  • 6.7 May 21, 2018: Edwards Announces Key Events For EuroPCR 2018 201
  • 6.8 May 21, 2018: NaviGate Cardiac Structures reports "excellent valvular function" at 1-year follow-up of first patient to receive GATE tricuspid valved stent via transjugular access 202
  • 6.9 May 17, 2018: MicroPort CardioFlow Releases One-year Clinical Outcome of VitaFlow 204
  • 6.10 May 17, 2018: MicroPort CardioFlow Attends Fourth China Valve (Hangzhou) Meeting 204
  • 6.11 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 205
  • 6.12 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018 205
  • 6.13 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018 206
  • 6.14 May 10, 2018: Neovasc Announces Results for the First Quarter 2018 207
  • 6.15 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 211
  • 6.16 May 04, 2018: Colibri Heart Valve Continues Enrollment in Clinical Feasibility Study of Second-Generation TAVI System 211
  • 6.17 Apr 26, 2018: Two-Year Feasibility Study Results Encouraging with Medtronic Harmony Transcatheter Pulmonary Valve 212
  • 6.18 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 213
  • 6.19 Apr 24, 2018: Edwards Lifesciences Announces First Quarter 2018 Financial Results 215
  • 6.20 Apr 19, 2018: Admedus TAVR Gaining Momentum With New Patent Applications 216
  • 6.21 Apr 10, 2018: Jena Valve Technology Continues CE Mark Study Treating Severe Aortic Stenosis with Next-Generation System; Patient Enrollment and Successful Implantations with the Everdur Pericardial Aortic Valve and Coronatix Delivery Catheter 217
  • 6.22 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 218
  • 6.23 Mar 28, 2018: Boston Scientific Prevails In U.K. Edwards Lifesciences Litigation 219
  • 6.24 Mar 28, 2018: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017 219
  • 6.25 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 223
  • 6.26 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 225
  • 6.27 Mar 23, 2018: Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid 225
  • 6.28 Mar 23, 2018: JenaValve Technology Appoints Keith D Dawkins MD as Board Member 225
  • 6.29 Mar 19, 2018: Colibri Heart Valve Advances Second-Generation TAVI System into Clinical Feasibility Study 226
  • 6.30 Mar 12, 2018: Admedus TAVR Project Passes Testing Milestone 227
  • 6.31 Mar 10, 2018: Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System 228
  • 6.32 Mar 07, 2018: 4C Medical's Transcatheter Mitral Valve Technology Receives First Place in Cardiovascular Research Technologies 2018 Competition 229
  • 6.33 Mar 01, 2018: 4C Medical's Novel Mitral Regurgitation Therapy to be Highlighted at CRT 2018 Meeting 230
  • 6.34 Feb 28, 2018: First Oregonian receives artificial mitral heart valve without open-heart surgery 230
  • 6.35 Feb 21, 2018: NaviGate Cardiac Structures reports GATE bioprosthesis as the first transcatheter valve replacement in Canada to treat tricuspid regurgitation 231
  • 6.36 Feb 15, 2018: Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark 232
  • 6.37 Feb 08, 2018: First Canadian Medicine: a 10th Case of Tricuspid Replacement Percutaneous in the World Achieved at the Institute 233
  • 6.38 Feb 07, 2018: Polyvascular Aims To Manufacture Tiny Valves For Heart Valve Replacement 233
  • 6.39 Feb 07, 2018: Caisson Interventional Expanding in Maple Grove 235
  • 6.40 Feb 02, 2018: JenaValve Technology Appoints Laura A Brenton as Vice President of Clinical and International Market Development 236
  • 6.41 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 236
  • 6.42 Feb 01, 2018: Edwards Lifesciences Reports Fourth Quarter Results 238
  • 6.43 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 240
  • 6.44 Jan 22, 2018: Neovasc Appoints Fred Colen As Chief Executive Officer 240
  • 6.45 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 241
  • 6.46 Jan 08, 2018: MicroPort CardioFlow Attends 2017 PCR-CIT China Chengdu Valves 242
  • 6.47 Jan 08, 2018: Neovasc Reports Tiara's Clinical Case Load Accelerating 243

7 Appendix 303

  • 7.1 Methodology 303
  • 7.2 About GlobalData 306
  • 7.3 Contact Us 306
  • 7.4 Disclaimer 306

List of Tables

1.1 List of Tables

  • Table 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development 19
  • Table 2: Transcatheter Heart Valves - Pipeline Products by Segment 20
  • Table 3: Transcatheter Heart Valves - Pipeline Products by Territory 21
  • Table 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path 23
  • Table 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 24
  • Table 6: Transcatheter Heart Valves - Ongoing Clinical Trials 25
  • Table 7: Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development 26
  • Table 8: Transcatheter Heart Valves - Pipeline Products by Stage of Development 29
  • Table 9: 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 10: AltaValve - Product Status 33
  • Table 11: AltaValve - Product Description 33
  • Table 12: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 13: Transcatheter Aortic Valve Replacement Device - Product Status 34
  • Table 14: Transcatheter Aortic Valve Replacement Device - Product Description 34
  • Table 15: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 16: pTAo-TAVR - Product Status 35
  • Table 17: pTAo-TAVR - Product Description 35
  • Table 18: Annulon Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 19: Mitral Valve Replacement Device - Product Status 36
  • Table 20: Mitral Valve Replacement Device - Product Description 36
  • Table 21: AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 22: AorTech Polymer Valve - Product Status 37
  • Table 23: AorTech Polymer Valve - Product Description 37
  • Table 24: AorTx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 25: AorTx Valve - Product Status 38
  • Table 26: AorTx Valve - Product Description 38
  • Table 27: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 28: Trilogy Aortic Valve System - Product Status 39
  • Table 29: Trilogy Aortic Valve System - Product Description 39
  • Table 30: Boston Children's Hospital Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 31: Pulmonary Valve Replacement Device - Product Status 40
  • Table 32: Pulmonary Valve Replacement Device - Product Description 40
  • Table 33: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 34: ACURATE TAVR - Product Status 41
  • Table 35: ACURATE TAVR - Product Description 42
  • Table 36: Gen 4 Lotus Valve System - Product Status 42
  • Table 37: Gen 4 Lotus Valve System - Product Description 42
  • Table 38: Lotus Edge Sheath 15F - Product Status 42
  • Table 39: Lotus Edge Sheath 15F - Product Description 43
  • Table 40: Lotus Edge Valve System - 21 mm - Product Status 43
  • Table 41: Lotus Edge Valve System - 21 mm - Product Description 43
  • Table 42: Lotus Edge Valve System - 23 mm - Product Status 44
  • Table 43: Lotus Edge Valve System - 23 mm - Product Description 44
  • Table 44: Lotus Edge Valve System - 25 mm - Product Status 44
  • Table 45: Lotus Edge Valve System - 25 mm - Product Description 45
  • Table 46: Lotus Edge Valve System - 27 mm - Product Status 45
  • Table 47: Lotus Edge Valve System - 27 mm - Product Description 45
  • Table 48: Lotus Edge Valve System - 29 mm - Product Status 46
  • Table 49: Lotus Edge Valve System - 29 mm - Product Description 46
  • Table 50: Lotus Valve System - 21 mm - Product Status 46
  • Table 51: Lotus Valve System - 21 mm - Product Description 47
  • Table 52: Lotus Valve System - 23 mm - Product Status 47
  • Table 53: Lotus Valve System - 23 mm - Product Description 48
  • Table 54: Lotus Valve System - 25 mm - Product Status 48
  • Table 55: Lotus Valve System - 25 mm - Product Description 49
  • Table 56: Lotus Valve System - 27 mm - Product Status 49
  • Table 57: Lotus Valve System - 27 mm - Product Description 49
  • Table 58: Lotus Valve System - 29 mm - Product Status 50
  • Table 59: Lotus Valve System - 29 mm - Product Description 50
  • Table 60: Transaortic Sheath - Product Status 50
  • Table 61: Transaortic Sheath - Product Description 51
  • Table 62: Boston Scientific Corp - Ongoing Clinical Trials Overview 52
  • Table 63: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers 54
  • Table 64: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 54
  • Table 65: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 54
  • Table 66: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 55
  • Table 67: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 55
  • Table 68: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 55
  • Table 69: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 56
  • Table 70: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 56
  • Table 71: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 56
  • Table 72: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 57
  • Table 73: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 57
  • Table 74: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 58
  • Table 75: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 58
  • Table 76: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 58
  • Table 77: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 59
  • Table 78: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 59
  • Table 79: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 60
  • Table 80: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 60
  • Table 81: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 60
  • Table 82: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 61
  • Table 83: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 61
  • Table 84: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 61
  • Table 85: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation 62

List of Figures

1.2 List of Figures

  • Figure 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development 19
  • Figure 2: Transcatheter Heart Valves - Pipeline Products by Segment 20
  • Figure 3: Transcatheter Heart Valves - Pipeline Products by Territory 21
  • Figure 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path 23
  • Figure 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 24
  • Figure 6: Transcatheter Heart Valves - Ongoing Clinical Trials 25
Back to Top